Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers
Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.
Vedotin Adcs Creighton University School Of Medicine Community Research Development Honorhealth Research Institute University Of Arizona College Medicine Division Of Gynecologic Oncology
Source: onclive.com